FTC Affiliate Disclosure: This article may contain affiliate links. If you make a purchase through these links, a commission may be earned at no additional cost to you. Editorial content is not influenced by affiliate relationships. MedFoundationNC.org is an independent publication — not a medical practice, hospital, or healthcare provider.
Foundayo (orforglipron) is currently FDA-approved for weight management only — not for type 2 diabetes. Eli Lilly has submitted Foundayo for additional indications. This article is not medical advice.
By MedFoundationNC.org Editorial Team | Last Updated: April 9, 2026
If you've been following the Foundayo news because you have type 2 diabetes — not just because you want to lose weight — you're in a different situation than most of the people reading about this medication right now. The FDA approved Foundayo on April 1, 2026, for weight management. It hasn't been approved for type 2 diabetes yet. But Eli Lilly has published clinical trial data from the ATTAIN-2 study specifically in adults with type 2 diabetes, and the company has stated it's pursuing additional indications. Here's what we know, what we don't, and what it means for you right now.
What the ATTAIN-2 Trial Found
The ATTAIN-2 trial was a Phase 3, randomized, double-blind, placebo-controlled study that evaluated orforglipron (the active ingredient in Foundayo) in adults with obesity or overweight who also had type 2 diabetes. According to published results, participants on the highest dose (36 mg, equivalent to 17.2 mg commercial tablet) achieved a 9.6% reduction in body weight compared to 2.5% with placebo.
For context, the ATTAIN-1 trial — which studied people without type 2 diabetes — showed 12.4% weight loss at the same dose. The difference is consistent with a well-documented pattern across GLP-1 medications: people with type 2 diabetes typically lose less weight than people without diabetes on the same medication at the same dose. This doesn't mean the medication works less well — it reflects metabolic differences between the two populations.
Eli Lilly also published results from the ACHIEVE-3 head-to-head trial comparing orforglipron to oral semaglutide (the active ingredient in Rybelsus, Novo Nordisk's oral diabetes medication) in adults with type 2 diabetes. According to published results in The Lancet, orforglipron produced superior blood sugar control (HbA1c reduction) and greater weight loss compared to oral semaglutide at the doses tested. However, the semaglutide doses in that trial were 7 mg and 14 mg — the Rybelsus doses, not the higher 25 mg dose used in the Wegovy pill for weight loss. Novo Nordisk has pointed out this distinction, and it's a fair one — the comparison doesn't tell us how Foundayo would perform against the Wegovy pill at full obesity-approved doses.
For a full breakdown of how Foundayo compares to other GLP-1 options on weight loss data specifically, our Foundayo vs Wegovy vs Zepbound comparison covers those numbers.
Blood Sugar Control: What the Data Shows
For people with type 2 diabetes, weight loss is important — but it's not the only outcome that matters. Blood sugar control, measured by HbA1c reduction, is the primary clinical endpoint for diabetes medications. The ATTAIN-2 and ACHIEVE-3 trials both measured this.
In the ACHIEVE-3 trial, orforglipron at doses of 12 mg and 36 mg produced statistically superior HbA1c reductions compared to oral semaglutide at 7 mg and 14 mg. This is clinically meaningful if it holds up in further studies — it would position Foundayo as potentially the most effective oral GLP-1 for blood sugar management.
That said, Foundayo is not currently approved for type 2 diabetes. Eli Lilly has stated it is pursuing this indication, and has submitted orforglipron for diabetes approval in multiple countries. Until the FDA specifically approves Foundayo for type 2 diabetes, any use for that purpose would be off-label — legal, but not supported by the same regulatory review that backs its weight management approval.
Hypoglycemia Risk: The Diabetes-Specific Safety Concern
If you have type 2 diabetes and you're considering Foundayo (whether for weight loss or off-label), the safety considerations are different from those for non-diabetic patients. According to the FDA-approved prescribing information, the risk of hypoglycemia (low blood sugar) is higher when Foundayo is taken with insulin or sulfonylurea medications.
Published data from the ATTAIN-2 trial showed that 7% of patients taking Foundayo in combination with a sulfonylurea reported hypoglycemia, compared to 0.5% of those not on a sulfonylurea. One patient on orforglipron experienced severe hypoglycemia. If you take insulin or sulfonylureas, your provider will likely need to adjust those doses when starting Foundayo to reduce the risk of dangerous blood sugar drops.
This is not unique to Foundayo — it's a class-wide consideration for all GLP-1 medications when used alongside insulin-stimulating drugs. But it's especially important because Foundayo's weight loss effect itself can improve insulin sensitivity, which means your existing diabetes medications may become too strong relative to your changing needs. Regular blood sugar monitoring during Foundayo treatment is essential for anyone with type 2 diabetes. For the full safety profile including all drug interactions, our Foundayo side effects and safety guide has the complete picture.
Why This Matters for the Telehealth GLP-1 Market
A large percentage of people seeking GLP-1 treatment through telehealth have both obesity and type 2 diabetes. The current telehealth platforms that prescribe compounded GLP-1 medications — MEDVi, TrimRx, Direct Meds, and others — serve this overlapping population. If Foundayo receives diabetes approval from the FDA, it would become the first oral, non-peptide GLP-1 that treats both conditions with a single daily pill that has no food restrictions.
For telehealth patients currently on compounded semaglutide or tirzepatide for combined weight and blood sugar management, Foundayo's potential diabetes approval could create a new transition pathway: from compounded injectable to FDA-approved oral. That's a significant shift in both convenience and regulatory certainty. For those exploring current telehealth GLP-1 options, our guide to getting Foundayo through telehealth covers the process and pricing.
What to Do Right Now If You Have Type 2 Diabetes
If you have type 2 diabetes and you're interested in Foundayo, here's the practical path as of April 2026:
Talk to your endocrinologist or primary care provider. Foundayo is FDA-approved for weight management, and many people with type 2 diabetes also meet the weight management criteria (BMI 27+ with a weight-related condition — type 2 diabetes qualifies). Your provider can prescribe Foundayo for its approved weight management indication if you're a candidate. The weight loss and metabolic improvements documented in the ATTAIN-2 trial may benefit your diabetes management even if the drug isn't specifically labeled for that purpose.
Understand the medication adjustment conversation. If you take insulin, sulfonylureas, or other blood-sugar-lowering medications, starting Foundayo will likely require dose adjustments to those existing drugs. Don't start Foundayo without discussing this with the provider who manages your diabetes medications.
Monitor closely during dose escalation. The Foundayo titration schedule — starting at 0.8 mg and increasing every 30 days — is the same regardless of diabetes status. But the impact on your blood sugar will be more pronounced. Frequent monitoring during the first few months is essential. For a full walkthrough of the dose schedule and what to expect, see our comprehensive Foundayo guide.
Keep an eye on the diabetes indication. Eli Lilly has stated it's pursuing diabetes approval for orforglipron. If approved, insurance coverage for diabetes may be broader than current weight management coverage — which could change the cost picture significantly. For details on the current Foundayo insurance situation and what to do if denied, our Foundayo insurance coverage guide has the full breakdown. For a broader view of how all the GLP-1 options currently compare, including for dual weight-and-diabetes management, our pills vs injections overview covers the full market. And if you're currently on a GLP-1 injection that's not producing the results you expected, our guide to when GLP-1 injections stop working covers common causes and alternatives.
Published April 9, 2026. MedFoundationNC.org Editorial Team.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Foundayo (orforglipron) is currently FDA-approved for chronic weight management only. It is not FDA-approved for type 2 diabetes as of April 2026. All clinical data cited is attributed to published trial results and FDA labeling. Off-label use should be discussed with your healthcare provider. Individual results vary. MedFoundationNC.org is an independent editorial publication — not a medical practice, hospital, or healthcare provider.